Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLIX40
- Development stage
- Preclinical
- Lead developer
- Hemispherian
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GLIX40 is a first-in-class small molecule activator of the Ten-eleven translocation 2 (TET2) enzyme, currently in the discovery and optimization stage of development by Hemispherian. As part of the GLIX platform, GLIX40 aims to address epigenetic dysregulation in cancer by increasing TET2 activity and restoring levels of 5-hydroxymethylcytosine (5-hmC). This restoration of 5-hmC levels is intended to induce a DNA damage response that selectively leads to the death of cancer cells while sparing healthy tissue. The drug is being explored for its potential in treating various malignancies characterized by TET2 deficiency or altered epigenetic profiles.
02
Targets
TET2 (Methylcytosine dioxygenase TET2)
Beyond the preview
Go deeper on GLIX40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLIX40.